• If you are wondering whether AbbVie stock still offers value after a strong run, it is important to see how different valuation methods line up against the current share price.
• The stock recently closed at US$215.40, with returns of 1.5% over the past week, 9.1% over the past month, and 21.5% over the past year, while year to date it is down 6.1%.
• Recent coverage has focused on AbbVie's position in the large cap pharmaceuticals and biotech space and how investors weigh long term drug pipelines and patent cycles against pricing and regulatory questions. This context helps explain why the stock's moves can be sharp at times, as sentiment shifts around the durability and quality of future cash flows.
• On Simply Wall St's valuation checks, AbbVie has a value score of 2 out of 6. The sections that follow unpack what that means across several common valuation approaches, and then conclude with a broader way to think about whether the stock fits your own view of value.

AbbVie scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, to arrive at an estimate of what the entire business might be worth now.

For AbbVie, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about US$20.1b. Analyst and extrapolated projections used by Simply Wall St point to free cash flow of roughly US$34.3b by 2030, with intermediate annual projections between 2026 and 2035 that are discounted back to today to reflect risk and the time value of money.

Putting those cash flows together, the model arrives at an estimated intrinsic value of about US$418.59 per share. Compared with the recent share price of US$215.40, this particular DCF output suggests AbbVie trades at a 48.5% discount, which screens as materially undervalued on this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 48.5%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.

Approach 2: AbbVie Price vs Earnings

For a profitable company like AbbVie, the P/E ratio is a straightforward way to connect what you pay for the stock with the earnings it currently generates. It gives you a quick sense of how much the market is willing to pay for each dollar of profit.

What counts as a "fair" P/E usually reflects how quickly earnings are expected to grow and how risky those earnings are perceived to be. Higher growth and lower perceived risk can justify a higher multiple, while slower growth or higher perceived risk often align with a lower multiple.

AbbVie currently trades on a P/E of 105.86x. That sits well above the Biotechs industry average P/E of 16.29x and the peer average of 20.32x. Simply Wall St’s Fair Ratio for AbbVie is 36.99x, which is its view of the P/E that would be reasonable given factors like earnings growth, industry, profit margins, market cap and risk profile.

This Fair Ratio is more tailored than a simple peer or industry comparison because it incorporates company specific characteristics rather than just broad group averages. On this framework, AbbVie’s actual P/E of 105.86x is materially higher than the Fair Ratio of 36.99x.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to write the story behind your numbers by linking your view on AbbVie’s future revenue, earnings and margins to a forecast and then to a fair value that you can compare with today's price.

On Simply Wall St’s Community page, Narratives let you set assumptions, see how they translate into fair value, and then decide whether the gap between that fair value and the current share price suggests AbbVie is closer to an opportunity or something to avoid.

These Narratives are refreshed when new information comes in, such as earnings or news about immunology launches, neuroscience uptake, pricing rules, manufacturing investments or analyst price targets. This helps your fair value stay aligned with the latest data rather than being a one off exercise.

For example, one investor might build a Narrative around the higher analyst price target of US$299.00 that leans on strong immunology and neuroscience assumptions. Another might anchor to the lower US$184.00 target that gives more weight to risks around patent expiries, pricing pressure and concentrated product exposure. Both can clearly see how their story translates into different fair values for the same stock.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.